May 04, 2018
Future Science Group Acquires BioTechniques
Future Science Group (FSG) is delighted to announce the acquisition of the life sciences journal, BioTechniques, from Informa PLC. BioTechniques joins the growing collection of Future Science Group STM journals.
BioTechniques (Impact Factor 2.030) is a MEDLINE-indexed, peer-reviewed, open access journal that provides the life science research community with an invaluable resource to access and discuss the latest methods, techniques and protocols available to laboratory researchers.
Launched in 1983, BioTechniques publishes original methods, tools and protocols, novel modifications to existing methods, and methods-oriented review articles of interest to life scientists working at the lab bench.
Phil Garner, FSG Managing Director, commented: “Having been a fan of BioTechniques for many years, I’m excited and extremely proud that it has joined the FSG family, bringing with it a breadth of lab science coverage to complement FSG’s niche biomedical areas of focus.”
FSG looks forward to building upon BioTechniques’ legacy and working with the BioTechniques community of authors, readers and advertisers to develop the brand, to enhance both its digital and print offerings. This includes exciting plans to build upon the existing media offerings, providing more hot-off-the-press news, views, videos and webinars to offer readers an easy-access, engaging resource for life science methods knowledge.
BioTechniques is a MEDLINE-indexed open access journal providing the life science research community with an invaluable resource for accessing the latest methods, techniques and protocols. Alongside peer-reviewed methods-based research and review articles, the journal publishes news and opinion articles covering experimental design, interesting observations and the latest tools available to the laboratory researcher.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.